Downregulation of EZH2 inhibits epithelial–mesenchymal transition in enzalutamide‐resistant prostate cancer
The Prostate2023Vol. 83(15), pp. 1458–1469
Citations Over TimeTop 11% of 2023 papers
Abstract
We identified the novel roles of EZH2 in EnzR mCRPC. EnzR PCa gains more EMT properties than that of enzalutamide-sensitive PCa. Loss of EZH2-assocaited inhibition of EMT is PRC2 independent. Downregulation of EZH2 suppresses EMT by impairing formation of H3K4me3 at the promotor regions, thus repressing expression of EMT-associated TFs.
Related Papers
- → The noncanonical role of EZH2 in cancer(2021)92 cited
- → Targeting EZH2 as cancer therapy(2021)54 cited
- → Targeting EZH2 for Cancer Therapy: Progress and Perspective(2015)64 cited
- → Enhancer of zeste homolog 2: A potential target for tumor therapy(2011)39 cited
- → Abstract 5436: HH2853 is a selective small molecular dual inhibitor of EZH1/2 with potent anti-tumor activities(2022)8 cited